ASO GROUP Ltd Makes New Investment in Icon Plc $ICLR

ASO GROUP Ltd bought a new position in Icon Plc (NASDAQ:ICLR) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 5,482 shares of the medical research company’s stock, valued at approximately $999,000.

A number of other large investors have also added to or reduced their stakes in the company. Toth Financial Advisory Corp acquired a new position in shares of Icon during the fourth quarter valued at about $27,000. Ameriflex Group Inc. acquired a new position in shares of Icon during the third quarter valued at about $33,000. Johnson Financial Group Inc. acquired a new position in shares of Icon during the third quarter valued at about $71,000. Quadrant Capital Group LLC acquired a new position in shares of Icon during the third quarter valued at about $78,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ICLR shares. Bank of America restated an “outperform” rating on shares of Icon in a report on Monday, June 1st. BMO Capital Markets upped their price objective on shares of Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a report on Friday, May 29th. JPMorgan Chase & Co. upped their target price on Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, May 29th. DA Davidson set a $164.00 target price on Icon in a research report on Monday, June 1st. Finally, Zacks Research lowered Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Icon presently has an average rating of “Hold” and a consensus price target of $156.44.

Icon Trading Up 3.7%

Icon stock opened at $149.92 on Friday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The stock’s 50 day simple moving average is $121.07 and its two-hundred day simple moving average is $140.43. The firm has a market cap of $11.48 billion, a PE ratio of 24.34, a P/E/G ratio of 11.42 and a beta of 1.26.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, June 10th. The medical research company reported $2.52 EPS for the quarter, topping the consensus estimate of $2.47 by $0.05. Icon had a return on equity of 9.50% and a net margin of 5.98%.The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.99 billion. During the same quarter in the prior year, the firm posted $3.43 EPS. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. Analysts anticipate that Icon Plc will post 9.74 earnings per share for the current year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.